Weight-Loss Drug Wegovy Approved for Serious Fatty Liver Disease in UK
The MHRA has authorized semaglutide to treat metabolic-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis.
The MHRA has authorized semaglutide to treat metabolic-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis.

Semaglutide, known as Wegovy, can now be prescribed to adults with moderate-to-advanced liver fibrosis caused by metabolic-associated steatohepatitis (MASH).
New research suggests a link between severe gum disease and early signs of kidney impairment.
An individual found that years of intense dieting and exercise were counterproductive due to an underlying stress response, leading to a shift towards mindful movement and stress reduction.
Experts outline potential metabolic effects and a plan for maintaining weight loss after discontinuing drugs like Ozempic.
New research suggests a fatty liver can provide the necessary environment for tumors to grow and spread more aggressively.
A podiatrist explains how the shoes and socks worn daily can create the ideal environment for fungal growth, leading to thickened, discolored nails, and outlines effective treatment strategies.
Experts explain the connection and how maintaining vision can potentially reduce dementia risk and aid those already diagnosed.
Australian researchers have identified killer T-cells recruited during pregnancy as a key factor in reducing breast cancer risk, potentially opening doors for non-pregnancy-based preventative treatments.